Instruction of haematopoietic lineage choices, evolution of transcriptional landscapes and cancer stem cell hierarchies derived from an AML1-ETO mouse model

EMBO Molecular Medicine

Volumn 5, Issue 12, 2013, Pages 1804-1820

  Cabezas Wallscheid, Nina ^a,b   Eichwald, Victoria ^b   de Graaf, Jos ^c   Löwer, Martin ^c   Lehr, Hans Anton ^d   Kreft, Andreas ^a   Eshkind, Leonid ^a   Hildebrandt, Andreas ^c   Abassi, Yasmin ^a   Heck, Rosario ^a   Dehof, Anna Katharina ^e   Ohngemach, Svetlana ^a   Sprengel, Rolf ^f   Wörtge, Simone ^a,f   Schmitt, Steffen ^b   Lotz, Johannes ^a   Meyer, Claudius ^a   Kindler, Thomas ^a   Zhang, Dong Er ^g   Kaina, Bernd ^a   Castle, John C ^c   Trumpp, Andreas ^b   Sahin, Ugur ^c   Bockamp, Ernesto ^a   more..

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d UNIVERSITY INSTITUTE OF PATHOLOGY   (Switzerland)

^e SAARLAND UNIVERSITY   (Germany)

^f MAX PLANCK INSTITUTE FOR MEDICAL RESEARCH   (Germany)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer stem cells; Core binding factor acute myeloid leukaemia; Preclinical mouse model; Therapy target validation; Whole transcriptome sequencing

Indexed keywords

AML1 ETO PROTEIN; HYBRID PROTEIN; TRANSCRIPTOME; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BONE MARROW CELL; CANCER STEM CELL; CELL LINEAGE; CELL POPULATION; CELL STRUCTURE; COLONY FORMING UNIT GM; CONTROLLED STUDY; DISEASE COURSE; ERYTHROPOIESIS; GENE EXPRESSION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; IMMUNOPHENOTYPING; IN VIVO STUDY; LEUKEMIA CELL; LEUKOCYTE COUNT; LYMPHOPOIESIS; MOUSE; MYELOID LEUKEMIA; MYELOID PROGENITOR CELL; MYELOPROLIFERATIVE DISORDER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEM CELL EXPANSION;

CANCER STEM CELLS; CORE BINDING FACTOR ACUTE MYELOID LEUKAEMIA; PRECLINICAL MOUSE MODEL; THERAPY TARGET VALIDATION; WHOLE TRANSCRIPTOME SEQUENCING;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINEAGE; DISEASE MODELS, ANIMAL; DOXORUBICIN; GENE EXPRESSION REGULATION; GRANULOCYTE-MACROPHAGE PROGENITOR CELLS; HEMATOPOIETIC STEM CELLS; IMMUNOPHENOTYPING; LEUKEMIA, MYELOID, ACUTE; MICE; MICE, INBRED C57BL; NEOPLASTIC STEM CELLS; ONCOGENE PROTEINS, FUSION; PHENOTYPE; SEQUENCE ANALYSIS, RNA; TRANSLOCATION, GENETIC;

EID: 84896949887     PISSN: 17574676     EISSN: 17574684     Source Type: Journal    
DOI: 10.1002/emmm.201302661     Document Type: Article

References (52)

1. Akashi K, Traver D, Miyamoto T, Weissman IL (2000) A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. Nature 404: 193-197
2. Alcalay M, Meani N, Gelmetti V, Fantozzi A, Fagioli M, Orleth A, Riganelli D, Sebastiani C, Cappelli E, Casciari C et al (2003) Acute myeloid leukemia fusion proteins deregulate genes involved in stem cell maintenance and DNA repair. J Clin Invest 112: 1751-1761
3. Appelbaum FR, Kopecky KJ, Tallman MS, Slovak ML, Gundacker HM, Kim HT, Dewald GW, Kantarjian HM, Pierce SR, Estey EH (2006) The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations. Br J Haematol 135: 165-173
4. Arber D, Brunning R, Le Beau M, Falini B, Vardiman J, Porwit A, Thiele J, Bloomfield C (2008) Acute myeloid leukaemia with recurrent genetic abnormalities. In WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edition, Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds), International Agency for Research on Cancer (IARC), Lyon, France, pp 110-123
5. Baccelli I, Trumpp A (2012) The evolving concept of cancer and metastasis stem cells. J Cell Biol 198: 281-293
6. Balgobind BV, Van den Heuvel-Eibrink MM, De Menezes RX, Reinhardt D, Hollink IH, Arentsen-Peters ST, van Wering ER, Kaspers GJ, Cloos J, de Bont ES et al (2011) Evaluation of gene expression signatures predictive of cytogenetic and molecular subtypes of pediatric acute myeloid leukemia. Haematologica 96: 221-230
7. Barton J, Bunka D, Knowling S, Lefevre P, Warren A, Bonifer C, Stockley P (2009) Characterization of RNA aptamers that disrupt the RUNX1-CBF{beta}/DNA complex. Nucleic Acids Res 37: 6818-6830
8. Bockamp E, Maringer M, Spangenberg C, Fees S, Fraser S, Eshkind L, Oesch F, Zabel B (2002) Of mice and models: Improved animal models for biomedical research. Physiol Genomics 11: 115-132
9. Bockamp E, Sprengel R, Eshkind L, Lehmann T, Braun J, Emmrich F, Hengstler J (2008) Conditional transgenic mouse models: From the basics to genome-wide sets of knockouts and current studies of tissue regeneration. Regen Med 3: 217-235
10. Buchholz F, Refaeli Y, Trumpp A, Bishop JM (2000) Inducible chromosomal translocation of AML1 and ETO genes through Cre/loxP-mediated recombination in the mouse. EMBO Rep 1: 133-139
11. Cozzio A, Passegue E, Ayton PM, Karsunky H, Cleary ML, Weissman IL (2003) Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Genes Dev 17: 3029-3035
12. de Guzman CG, Warren AJ, Zhang Z, Gartland L, Erickson P, Drabkin H, Hiebert SW, Klug CA (2002) Hematopoietic stem cell expansion and distinct myeloid developmental abnormalities in a murine model of the AML1-ETO translocation. Mol Cell Biol 22: 5506-5517
13. de Jonge HJ, Valk PJ, Veeger NJ, ter Elst A, den Boer ML, Cloos J, de Haas V, van den Heuvel-Eibrink MM, Kaspers GJ, Zwaan CM et al (2010) High VEGFC expression is associated with unique gene expression profiles and predicts adverse prognosis in pediatric and adult acute myeloid leukemia. Blood 116: 1747-1754
14. Dick JE (2008) Stem cell concepts renew cancer research. Blood 112: 4793-4807
15. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM et al (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355: 2408-2417
16. Döhner H, Estey E, Amadori S, Appelbaum F, Büchner T, Burnett A, Dombret H, Fenaux P, Grimwade D, Larson R et al (2010) Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115: 453-474
17. Eppert K, Takenaka K, Lechman ER, Waldron L, Nilsson B, van Galen P, Metzeler KH, Poeppl A, Ling V, Beyene J et al (2011) Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med 17: 1086-1093
18. Estey E, Dohner H (2006) Acute myeloid leukaemia. Lancet 368: 1894-1907
19. Fenske TS, Pengue G, Mathews V, Hanson PT, Hamm SE, Riaz N, Graubert TA (2004) Stem cell expression of the AML1/ETO fusion protein induces a myeloproliferative disorder in mice. Proc Natl Acad Sci USA 101: 15184-15189
20. Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, Wheatley K, Harrison CJ, Burnett AK Group NCRIALW (2010) Refinement of cytogenetic classification in acute myeloid leukemia: Determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 116: 354-365
21. Hatlen MA, Wang L, Nimer SD (2012) AML1-ETO driven acute leukemia: Insights into pathogenesis and potential therapeutic approaches. Front Med 6: 248-262
22. Higuchi M, O'Brien D, Kumaravelu P, Lenny N, Yeoh EJ, Downing JR (2002) Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia. Cancer Cell 1: 63-74
23. Horton SJ, Huntly BJ (2012) Recent advances in acute myeloid leukemia stem cell biology. Haematologica 97: 966-974
24. Ishikawa F, Yoshida S, Saito Y, Hijikata A, Kitamura H, Tanaka S, Nakamura R, Tanaka T, Tomiyama H, Saito N et al (2007) Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol 25: 1315-1321
25. Kelly LM, Gilliland DG (2002) Genetics of myeloid leukemias. Annu Rev Genomics Hum Genet 3: 179-198
26. Kogan SC, Ward JM, Anver MR, Berman JJ, Brayton C, Cardiff RD, Carter JS, de Coronado S, Downing JR, Fredrickson TN et al (2002) Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice. Blood 100: 238-245
27. Kusec R, Laczika K, Knöbl P, Friedl J, Greinix H, Kahls P, Linkesch W, Schwarzinger I, Mitterbauer G, Purtscher B (1994) AML1/ETO fusion mRNA can be detected in remission blood samples of all patients with t(8;21) acute myeloid leukemia after chemotherapy or autologous bone marrow transplantation. Leukemia 8: 735-739
28. Kvinlaug BT, Chan WI, Bullinger L, Ramaswami M, Sears C, Foster D, Lazic SE, Okabe R, Benner A, Lee BH et al (2011) Common and overlapping oncogenic pathways contribute to the evolution of acute myeloid leukemias. Cancer Res 71: 4117-4129
29. Lackner MR, Wilson TR, Settleman J (2012) Mechanisms of acquired resistance to targeted cancer therapies. Future Oncol 8: 999-1014
30. Lam K, Zhang DE (2012) RUNX1 and RUNX1-ETO: Roles in hematopoiesis and leukemogenesis. Front Biosci 17: 1120-1139
31. Lin P, Chen L, Luthra R, Konoplev SN, Wang X, Medeiros LJ (2008) Acute myeloid leukemia harboring t(8;21)(q22;q22): A heterogeneous disease with poor outcome in a subset of patients unrelated to secondary cytogenetic aberrations. Mod Pathol 21: 1029-1036
32. Marcucci G, Mrózek K, Ruppert AS, Maharry K, Kolitz JE, Moore JO, Mayer RJ, Pettenati MJ, Powell BL, Edwards CG et al (2005) Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): A cancer and leukemia group B study. J Clin Oncol 23: 5705-5717
33. Mills KI, Kohlmann A, Williams PM, Wieczorek L, Liu WM, Li R, Wei W, Bowen DT, Loeffler H, Hernandez JM et al (2009) Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AML transformation of myelodysplastic syndrome. Blood 114: 1063-1072
34. Miyamoto T, Nagafuji K, Akashi K, Harada M, Kyo T, Akashi T, Takenaka K, Mizuno S, Gondo H, Okamura T et al (1996) Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia. Blood 87: 4789-4796
35. Miyoshi H, Kozu T, Shimizu K, Enomoto K, Maseki N, Kaneko Y, Kamada N, Ohki M (1993) The t(8;21) translocation in acute myeloid leukemia results in production of an AML1-MTG8 fusion transcript. Embo J 12: 2715-2721
36. Narimatsu H, Iino M, Ichihashi T, Yokozawa T, Hayakawa M, Kiyoi H, Takeo T, Sawamoto A, Iida H, Tsuzuki M et al (2008) Clinical significance of minimal residual disease in patients with t(8;21) acute myeloid leukemia in Japan. Int J Hematol 88: 154-158
37. Nucifora G, Larson RA, Rowley JD (1993) Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission. Blood 82: 712-715
38. Okuda T, van Deursen J, Hiebert SW, Grosveld G, Downing JR (1996) AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 84: 321-330
39. Ptasinska A, Assi SA, Mannari D, James SR, Williamson D, Dunne J, Hoogenkamp M, Wu M, Care M, McNeill H et al (2012) Depletion of RUNX1/ETO in t(8;21) AML cells leads to genome-wide changes in chromatin structure and transcription factor binding. Leukemia
40. Reikvam H, Hatfield KJ, Kittang AO, Hovland R, Bruserud Ø (2011) Acute myeloid leukemia with the t(8;21) translocation: Clinical consequences and biological implications. J Biomed Biotechnol 2011: 104631
41. Rhoades KL, Hetherington CJ, Harakawa N, Yergeau DA, Zhou L, Liu LQ, Little MT, Tenen DG, Zhang DE (2000) Analysis of the role of AML1-ETO in leukemogenesis, using an inducible transgenic mouse model. Blood 96: 2108-2115
42. Ross ME, Mahfouz R, Onciu M, Liu HC, Zhou X, Song G, Shurtleff SA, Pounds S, Cheng C, Ma J et al (2004) Gene expression profiling of pediatric acute myelogenous leukemia. Blood 104: 3679-3687
43. Saunders MJ, Tobal K, Yin JA (1994) Detection of t(8;21) by reverse transcriptase polymerase chain reaction in patients in remission of acute myeloid leukaemia type M2 after chemotherapy or bone marrow transplantation. Leuk Res 18: 891-895
44. Schessl C, Rawat VP, Cusan M, Deshpande A, Kohl TM, Rosten PM, Spiekermann K, Humphries RK, Schnittger S, Kern W et al (2005) The AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice. J Clin Invest 115: 2159-2168
45. Schwieger M, Lohler J, Friel J, Scheller M, Horak I, Stocking C (2002) AML1-ETO inhibits maturation of multiple lymphohematopoietic lineages and induces myeloblast transformation in synergy with ICSBP deficiency. J Exp Med 196: 1227-1240
46. Valk PJ, Verhaak RG, Beijen MA, Erpelinck CA, Barjesteh van Waalwijk van Doorn-Khosrovani S, Boer JM, Beverloo HB, Moorhouse MJ, van der Spek PJ, Löwenberg B et al (2004) Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 350: 1617-1628
47. Verhaak RG, Wouters BJ, Erpelinck CA, Abbas S, Beverloo HB, Lugthart S, Löwenberg B, Delwel R, Valk PJ (2009) Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling. Haematologica 94: 131-134
48. Wang L, Gural A, Sun XJ, Zhao X, Perna F, Huang G, Hatlen MA, Vu L, Liu F, Xu H et al (2011) The leukemogenicity of AML1-ETO is dependent on site-specific lysine acetylation. Science 333: 765-769
49. Wichmann C, Grez M, Lausen J (2010) Molecular targeting of aberrant transcription factors in leukemia: Strategies for RUNX1/ETO. Curr Drug Targets 11: 1181-1191
50. Wiemels JL, Xiao Z, Buffler PA, Maia AT, Ma X, Dicks BM, Smith MT, Zhang L, Feusner J, Wiencke J et al (2002) In utero origin of t(8;21) AML1-ETO translocations in childhood acute myeloid leukemia. Blood 99: 3801-3805
51. Wortge S, Eshkind L, Cabezas-Wallscheid N, Lakaye B, Kim J, Heck R, Abassi Y, Diken M, Sprengel R, Bockamp E (2010) Tetracycline-controlled transgene activation using the ROSA26-iM2-GFP knock-in mouse strain permits GFP monitoring of DOX-regulated transgene-expression. BMC Dev Biol 10: 95
52. Yuan Y, Zhou L, Miyamoto T, Iwasaki H, Harakawa N, Hetherington CJ, Burel SA, Lagasse E, Weissman IL, Akashi K et al (2001) AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations. Proc Natl Acad Sci USA 98: 10398-10403